Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daunorubicin liposomal

Drug Profile

Daunorubicin liposomal

Alternative Names: Daunorubicin citrate liposome injection; DaunoXome; VS 103

Latest Information Update: 16 Nov 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Galen Limited; Gilead Sciences; Swedish Orphan Biovitrum
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action Apoptosis stimulants; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Kaposi's sarcoma
  • Discontinued Acute myeloid leukaemia; Brain cancer; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Nov 2012 Daunorubicin liposomal receives orphan drug status for Acute myeloid leukaemia in European Union
  • 24 Feb 2012 Galen Ltd. acquires daunorubicin liposomal (DaunoXome®) from Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top